Net Revenue grew 23% year-over-year to approximately
B2B eligible lives and completed B2B sessions grew 92% and 96%, respectively, versus the prior-year period
Active members grew 21% year-over-year to approximately 60,300
Third Quarter 2021 Financial Highlights
- Net Revenue of
$26.4 million , a 23% increase over the prior-year period - Gross Profit of
$14.2 million ; Gross Margin of 54% compared to 70% in the prior-year period - Adjusted EBITDA loss of
($20.8) million , compared to($2.0) million in the prior-year period - Net income of
$1.5 million , compared to a net loss of($2.7) million in the prior-year period
Key Operating Metrics
- Total active members grew 21% year-over-year to approximately 60,300 as of
September 30, 2021 - B2B eligible lives grew 92% year-over-year to over 75 million as of
September 30, 2021 - 71,300 completed B2B sessions, a 96% increase versus the prior‐year period
Revenue
- Net Revenue for the third quarter was
$26.4 million , a 23% year‐over‐year increase. This metric came in below expectations due to a lower number of acquired customers in the direct‐to‐consumer business and an adjustment to reserves, which was only partially offset by growth in B2B Gross Revenue. - In the third quarter we increased the allowance for credit losses on receivables by
$3.4 million , of which$2.8 million related to prior quarters. Excluding the impact of this one‐time non‐cash adjustment, consolidated Revenue would have been$29.2 million , up 37% year‐over‐year. - Direct‐to‐consumer Revenue was
$18.6 million , a 10% year‐over‐year increase in the third quarter. The slowdown in the B2C business resulted in part from delays in launching new products and features, as well as a decline in conversion rates. - B2B Revenue was
$7.7 million , a 69% increase year‐over‐year, with the continued strong performance of recurring revenue coming from PEPM fees, which approximately tripled year‐over‐year.
Gross Margin
- Gross profit was
$14.2 million in the third quarter, compared to$15.1 million in the prior-year quarter. Gross margin was 54% compared to 70% a year ago. This decline was due to the increase in the reserve for credit losses on receivables, revenue mix shift towards B2B, and the continued investment in W2 therapist network. - Excluding the reserve adjustment related to prior quarters, gross profit and margin for the quarter would have been
$17.0 million and 58%, respectively.
Net Income
- Net income was
$1.5 million compared to a net loss of$2.7 million in the prior‐year period. This reflects a$26.9 million non‐cash gain resulting from the revaluation of the warrants’ liabilities, driven by lower share price.
The following table summarizes the Company’s performance during the third quarter of 2021, compared to the same period in 2020:
| Three Months Ended |
Period-Over-Period | |||||
(Values in thousands, except B2B eligible lives and percentages) | 2021 | 2020 | Change | ||||
Number of B2B eligible lives at period end (in millions) | 75.3 | 39.2 | 92% | ||||
Total number of active members at period end | 60.3 | 49.9 | 21% | ||||
Total number of completed B2B sessions | 71.3 | 36.4 | 96% | ||||
| | ||||||
Net revenue | $ | 26,359 | $ | 21,505 | 23% | ||
Gross profit | 14,172 | 15,091 | (6%) | ||||
Gross margin % | 53.8% | 70.2% | (1,600) basis points | ||||
Operating expenses | 39,399 | 17,495 | 125% | ||||
Net income (loss) | 1,505 | (2,692) | * | ||||
Adjusted EBITDA (1) | $ | (20,849) | $ | (2,049) | * |
* Not meaningful
(1) Adjusted EBITDA is a non-GAAP financial measure. Refer to “Reconciliation of Non-GAAP Results to GAAP Results” table below.
Conference Call and Webcast Details
The Company will host a conference call at
About
Today, the need for care feels more urgent than ever. When seeking treatment, whether it's psychiatry or adolescent, individual or couples therapy,
For more information about
To learn more about online therapy, please visit: https://www.talkspace.com/online-therapy/.
To learn more about Talkspace Psychiatry, please visit https://www.talkspace.com/psychiatry.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking, including statements regarding our financial condition, anticipated financial performance, business strategy and plans, market opportunity and expansion and objectives of our management for future operations. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast”, “future”, “intend,” “may,” “might”, “opportunity”, “plan,” “possible”, “potential,” “predict,” “project,” “should,” “strategy”, “strive”, “target,” “will,” or “would”, the negative of these words or other similar terms or expressions. The absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many important factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: our history of losses; the rapid evolution of our business and the markets in which we operate; our ability to continue growing at the rates we have historically grown, or at all; the development of the virtual behavioral health market; COVID-19 and its impact on business and economic conditions; competition in our industry; and our relationships with affiliated professional entities to provide physician and other professional services. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in under the caption “Risk Factors” in our prospectus dated
Contacts
For Investors:
Westwicke, an
443-213-0500
TalkspaceIR@westwicke.com
Condensed Consolidated Statements of Income (Loss)
(Unaudited)
Three months ended |
Variance | Nine months ended |
Variance | |||||||||||||||||||||||||||||
2021 | 2020 | $ | % | 2021 | 2020 | $ | % | |||||||||||||||||||||||||
(in thousands, except percentages and per share data) | ||||||||||||||||||||||||||||||||
Consumer revenue | $ | 18,631 | $ | 16,923 | $ | 1,708 | 10.1 | $ | 58,286 | $ | 42,208 | $ | 16,078 | 38.1 | ||||||||||||||||||
Commercial revenue | 7,728 | 4,582 | 3,146 | 68.7 | 26,213 | 8,294 | 17,919 | 216.0 | ||||||||||||||||||||||||
Total revenue | 26,359 | 21,505 | 4,854 | 22.6 | 84,499 | 50,502 | 33,997 | 67.3 | ||||||||||||||||||||||||
Cost of revenues | 12,187 | 6,414 | 5,773 | 90.0 | 33,698 | 17,394 | 16,304 | 93.7 | ||||||||||||||||||||||||
Gross profit | 14,172 | 15,091 | (919 | ) | (6.1 | ) | 50,801 | 33,108 | 17,693 | 53.4 | ||||||||||||||||||||||
Operating expenses: | ||||||||||||||||||||||||||||||||
Research and development, net | 4,278 | 2,199 | 2,079 | 94.5 | 12,023 | 7,327 | 4,696 | 64.1 | ||||||||||||||||||||||||
Clinical operations | 1,896 | 899 | 997 | 110.9 | 5,886 | 2,535 | 3,351 | 132.2 | ||||||||||||||||||||||||
Sales and marketing | 26,431 | 12,660 | 13,771 | 108.8 | 75,125 | 30,020 | 45,105 | 150.2 | ||||||||||||||||||||||||
General and administrative | 6,794 | 1,737 | 5,057 | 291.1 | 23,112 | 4,198 | 18,914 | 450.5 | ||||||||||||||||||||||||
Total operating expenses | 39,399 | 17,495 | 21,904 | 125.2 | 116,146 | 44,080 | 72,066 | 163.5 | ||||||||||||||||||||||||
Operating loss | (25,227 | ) | (2,404 | ) | (22,823 | ) | (949.4 | ) | (65,345 | ) | (10,972 | ) | (54,373 | ) | (495.6 | ) | ||||||||||||||||
Financial income (expense), net | 26,743 | (285 | ) | 27,028 | * | 23,700 | (254 | ) | 23,954 | * | ||||||||||||||||||||||
Income (loss) before taxes on income | 1,516 | (2,689 | ) | 4,205 | 156.4 | (41,645 | ) | (11,226 | ) | (30,419 | ) | (271.0 | ) | |||||||||||||||||||
Taxes on income | 11 | 3 | 8 | 266.7 | 29 | 12 | 17 | 141.7 | ||||||||||||||||||||||||
Net income (loss) | 1,505 | (2,692 | ) | 4,197 | 155.9 | (41,674 | ) | (11,238 | ) | (30,436 | ) | (270.8 | ) | |||||||||||||||||||
Net income (loss) per share (1): | ||||||||||||||||||||||||||||||||
Basic | $ | 0.01 | $ | (0.20 | ) | $ | 0.21 | 104.9 | $ | (0.64 | ) | $ | (0.84 | ) | $ | 0.20 | 23.4 | |||||||||||||||
Diluted | $ | 0.01 | $ | (0.20 | ) | $ | 0.21 | 104.5 | $ | (0.64 | ) | $ | (0.84 | ) | $ | 0.20 | 23.4 | |||||||||||||||
Weighted average number of common shares (1): | ||||||||||||||||||||||||||||||||
Basic | 152,268 | 13,375 | 64,638 | 13,349 | ||||||||||||||||||||||||||||
Diluted | 165,179 | 13,375 | 64,638 | 13,349 |
* = not meaningful
(1) Prior period results have been adjusted to reflect the exchange of Old Talkspace’s common stock for Talkspace’s common stock at an exchange ratio of approximately 1.134140 in
Condensed Consolidated Balance Sheets
2021 |
2020 |
|||||||
(in thousands) | (Unaudited) | |||||||
ASSETS | | |||||||
CURRENT ASSETS: | | | ||||||
Cash and cash equivalents | $ | 222,865 | $ | 13,248 | ||||
Accounts receivable, net | 5,318 | 5,914 | ||||||
Other current assets | 10,023 | 1,515 | ||||||
Total current assets | 238,206 | 20,677 | ||||||
Property and equipment, net | 658 | 175 | ||||||
Deferred issuance costs | - | 692 | ||||||
Intangible assets, net | 3,876 | 5,195 | ||||||
6,134 | 6,134 | |||||||
Other long-term assets | 82 | - | ||||||
Total assets | $ | 248,956 | $ | 32,873 | ||||
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT | | | ||||||
CURRENT LIABILITIES: | | | ||||||
Accounts payable | $ | 14,039 | $ | 7,901 | ||||
Deferred revenues | 8,302 | 5,172 | ||||||
Accrued expenses and other current liabilities | 7,634 | 7,416 | ||||||
Total current liabilities | 29,975 | 20,489 | ||||||
Warrant liabilities | 12,012 | - | ||||||
Other long-term liabilities | 86 | - | ||||||
Total liabilities | 42,073 | 20,489 | ||||||
Convertible preferred stock | - | 111,282 | ||||||
STOCKHOLDERS’ EQUITY (DEFICIT): | | | ||||||
Common stock (1) | 15 | 1 | ||||||
Additional paid-in capital (1) | 357,330 | 9,889 | ||||||
Accumulated deficit | (150,462 | ) | (108,788 | ) | ||||
Total stockholders’ equity (deficit) | 206,883 | (98,898 | ) | |||||
Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $ | 248,956 | $ | 32,873 |
(1) Prior period results have been adjusted to reflect the exchange of Old Talkspace’s common stock for Talkspace’s common stock at an exchange ratio of approximately 1.134140 in
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Nine months ended |
||||||||
(in thousands) | 2021 | 2020 | ||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (41,674 | ) | $ | (11,238 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | 1,458 | 55 | ||||||
Amortization of debt issuance cost | 175 | — | ||||||
Stock-based compensation | 20,584 | 1,069 | ||||||
Change in fair value of warrants | (23,842 | ) | — | |||||
Increase in accounts receivable | 596 | (3,045 | ) | |||||
Increase in other current assets | (8,515 | ) | (1,108 | ) | ||||
Increase in accounts payable | 7,113 | 2,021 | ||||||
Increase in deferred revenues | 3,130 | 3,390 | ||||||
(Decrease) increase in accrued expenses and other current liabilities | (134 | ) | 2,193 | |||||
Net cash used in operating activities | (41,109 | ) | (6,663 | ) | ||||
Cash flows from investing activities: | ||||||||
Purchase of property and equipment | (622 | ) | (43 | ) | ||||
Proceeds from restricted long-term bank deposit | — | 414 | ||||||
Net cash (used in) provided by investing activities | (622 | ) | 371 | |||||
Cash flows from financing activities: | ||||||||
Proceeds from reverse capitalization, net of transaction costs | 249,428 | — | ||||||
Proceeds from borrowings | 6,000 | — | ||||||
Repayment of borrowings | (6,000 | ) | — | |||||
Payment of debt issuance costs | (50 | ) | — | |||||
Proceeds from exercise of stock options | 1,970 | 62 | ||||||
Net cash provided by financing activities | 251,348 | 62 | ||||||
Change in cash and cash equivalents | 209,617 | (6,230 | ) | |||||
Cash and cash equivalents at the beginning of the period | 13,248 | 39,632 | ||||||
Cash and cash equivalents at the end of the period | $ | 222,865 | $ | 33,402 |
Non-GAAP Financial Measures
In addition to our financial results determined in accordance with GAAP, we believe adjusted EBITDA, a non-GAAP measure, is useful in evaluating our operating performance. We use adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measures, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations or outlook. We believe that the use of adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing the health of our business and our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measure as a tool for comparison. A reconciliation is provided below for this non-GAAP financial measure to net loss, the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review our GAAP financial measure and the reconciliation of our non-GAAP financial measure to its most directly comparable GAAP financial measure, and not to rely on any single financial measure to evaluate our business.
Adjusted EBITDA
Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and in evaluating acquisition opportunities.
We calculate adjusted EBITDA as net loss adjusted to exclude (i) interest and other expenses (income), net, (ii) tax benefit and expense, (iii) depreciation and amortization (iv) stock-based compensation expense and (v) business combination and other financing expenses.
Reconciliation of Non-GAAP Results to GAAP Results
Three months ended |
Nine months ended |
|||||||||||||||
(in thousands) | 2021 | 2020 | 2021 | 2020 | ||||||||||||
Net income (loss) | $ | 1,505 | $ | (2,692 | ) | $ | (41,674 | ) | $ | (11,238 | ) | |||||
Add: | ||||||||||||||||
Depreciation and amortization | 503 | 19 | 1,458 | 55 | ||||||||||||
Financial (income) expense, net (1) | (26,743 | ) | 285 | (23,700 | ) | 254 | ||||||||||
Taxes on income | 11 | 3 | 29 | 12 | ||||||||||||
Stock-based compensation | 3,875 | 336 | 20,584 | 1,069 | ||||||||||||
Adjusted EBITDA | $ | (20,849 | ) | $ | (2,049 | ) | $ | (43,303 | ) | $ | (9,848 | ) |
(1) For the three months ended
Active Members and B2B Eligible Lives
Three months ended, | |||||||||||||||||||||||||||
2020 |
2020 |
2020 |
2020 |
2021 |
2021 |
2021 |
|||||||||||||||||||||
Active members (in thousands) (1) | 29.4 | 44.0 | 49.9 | 50.0 | 58.7 | 59.4 | 60.3 | ||||||||||||||||||||
B2B eligible lives (in millions) (1) | 9.5 | 33.7 | 39.2 | 39.4 | 49.5 | 71.9 | 75.3 |
(1) Historical amounts have been updated to be comparable to current period presentation.
Key Business Metrics
Active Members: We consider members “active” (i) in the case of our B2C members, commencing on the date such member initiates contact with a provider on our platform until the term of their monthly, quarterly or bi-annual subscription plan expires, unless terminated early, and (ii) in the case of our B2B members, if such members have engaged on our platform during the preceding 25 days, such as sending a text, video or audio message to, or participating in a video call with, a provider, completing a satisfaction or progress report survey or signing up for our platform. While a growth in active members typically highlights strong engagement with our members, not all active members are associated with revenue in that particular period.
B2B Eligible Lives: We consider B2B lives “eligible” if such persons are eligible to receive treatment on the
Source: Talkspace